Report #2829767

Received Mar 5, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: FL
Recovered: Unknown
Vaccinated: Jun 1, 2024
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	—	—

Symptoms (2)

Incorrect dose administeredNo adverse event

Symptom narrative

Received First Dose June 2024, More than 1 Month and Hasn't Received Second; Initial report received on 12-Feb-2025. A pharmacist reported that a male patient (race and ethnicity not reported) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization in Jun-2024 but had not received the second dose yet. No medical history or concomitant medications were reported. In Jun-2024, the patient received dose 1 of a hepatitis B vaccine [HEPLIAV-B (NDC # 43528-002-01, lot #, expiration date, route, and site not reported). At the time of reporting, the patient had not received the second dose of HEPLISAV-B yet, more than a month after receiving the first dose. No adverse reactions were reported. The reporter had no other information. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.